Oncothyreon announces data from multiple small molecule programs to be presented at American Association of Cancer Research Annu...( BELLEVUE WA April 10 / Oncothyreo...)

BELLEVUE, WA, April 10 /PRNewswire-FirstCall/ - Oncothyreon Inc. (Nasdaq: ONTY) (TSX:ONY) announced today that data from preclinical studies of PX-478, pharmacodynamic studies of PX-12 and preclinical studies of PX-866 will be presented at the Annual Meeting of the American Association for Cancer Research (AACR) in San Diego April 12-16, 2008.

Oncothyreon is currently conducting a Phase 1 clinical trial of PX-478 in patients with advanced metastatic cancer and a Phase 2 trial of PX-12 in patients with advanced pancreatic cancer. PX-866 is expected to enter a Phase 1 trial in patients with advanced cancers in the second quarter of 2008.

Details regarding these abstracts are as follows:

PX-478

- Molecular-genetic image guided studies of the antitumor HIF-1alpha

inhibitor PX-478 in combination with radiation

Abstract # 2566, Session: Novel Mechanisms of Drug Action

Presentation: Monday, April 14, 2008, 2:55 p.m. to 3:10 p.m. P.T.

- HIF-1alpha antagonism by PX-478 inhibits progression and spread of

orthotopic human small cell lung cancer and lung adenocarcinoma in

mice

Abstract # 1440, Session: mTOR/Akt/PI3K Inhibitors and

Vascular/Hypoxia Targeting Agents

Poster session: Sunday, April 13, 2008, 1:00 p.m. to

5:00 p.m. P.T.

PX-12

- Pharmacodynamic evaluation of plasma thioredoxin-1 for patient

enrichment of PX-12 clinical trials

Abstract # 4453, Session: Molecular Signatures and Proteomic

Biomarkers

Poster Session: Tuesday, April 15, 2008, 1:00 p.m. to

5:00 p.m. P.T.

PX-866

- Cellular and in vivo
'/>"/>